Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INSM
INSM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INSM News
Insmed Halts Lung Disorder Therapy R&D Program After Trial Failure
Apr 08 2026
seekingalpha
Insmed Halts Brinsupri Development for HS After Trial Failure
Apr 08 2026
Yahoo Finance
Insmed Discontinues Brensocatib Development After Phase 2b Study Fails
Apr 08 2026
NASDAQ.COM
Insmed Discontinues Brensocatib HS Program After Phase 2b Study Fails
Apr 07 2026
PRnewswire
Insmed's Investigational Treatment for Skin Disease Falls Short in Clinical Trial
Apr 07 2026
stocktwits
INSMED INC - PHASE 2B CEDAR STUDY OF BRENSOCATIB FAILED TO ACHIEVE EFFICACY GOALS
Apr 07 2026
moomoo
INSMED INC REPORTS NO NEW SAFETY CONCERNS FOR BRENSOCATIB IN PHASE 2B CEDAR TRIAL
Apr 07 2026
moomoo
Insmed, First Solar, and Aptiv Form Death Cross, Signaling Bearish Trends
Apr 06 2026
stocktwits
Insmed Shares Rise 5.5% Following Positive Competitive Data
Mar 31 2026
NASDAQ.COM
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
Mar 30 2026
NASDAQ.COM
US Stock Market Declines Amid Rising Oil Prices
Mar 30 2026
NASDAQ.COM
Mixed U.S. Stock Indices Amid Rising Oil Prices
Mar 30 2026
NASDAQ.COM
US Stocks Rise as Oil Prices Hit Three-Week High
Mar 30 2026
NASDAQ.COM
Middle East Tensions Impact Global Markets
Mar 30 2026
NASDAQ.COM
Latest Wall Street Rating Updates
Mar 30 2026
CNBC
INSMED STOCK RISES 3.9% IN PREMARKET TRADING FOLLOWING MORGAN STANLEY UPGRADE TO OVERWEIGHT FROM EQUAL-WEIGHT
Mar 30 2026
moomoo
Show More News
